HUP0003852A2 - Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására - Google Patents

Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására

Info

Publication number
HUP0003852A2
HUP0003852A2 HU0003852A HUP0003852A HUP0003852A2 HU P0003852 A2 HUP0003852 A2 HU P0003852A2 HU 0003852 A HU0003852 A HU 0003852A HU P0003852 A HUP0003852 A HU P0003852A HU P0003852 A2 HUP0003852 A2 HU P0003852A2
Authority
HU
Hungary
Prior art keywords
alzheimer
disease
treatment
highly selective
dementias
Prior art date
Application number
HU0003852A
Other languages
English (en)
Inventor
Arnold Brossi
Nigel H. Greig
Marvin Hausman
Timothy T. Soncrant
Qian-Sheng Yu
Original Assignee
Axonyx
National Institute Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axonyx, National Institute Of Health filed Critical Axonyx
Publication of HUP0003852A2 publication Critical patent/HUP0003852A2/hu
Publication of HUP0003852A3 publication Critical patent/HUP0003852A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány alapját az a felismerés képezi, hogy az erősen szelektívbutiril-kolin-észteráz inhibitorok előnyösen alkalmazhatókkorosodással járó észlelési zavarok és Alzheimer-kór kezelésére vagymegelőzésére. Butiril-kolin-észteráz inhibitorként különösen előnyös acimszerin. Ó
HU0003852A 1997-07-09 1998-07-09 Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias HUP0003852A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5208797P 1997-07-09 1997-07-09
PCT/US1998/014063 WO1999002154A1 (en) 1997-07-09 1998-07-09 Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias

Publications (2)

Publication Number Publication Date
HUP0003852A2 true HUP0003852A2 (hu) 2001-04-28
HUP0003852A3 HUP0003852A3 (en) 2003-04-28

Family

ID=21975382

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003852A HUP0003852A3 (en) 1997-07-09 1998-07-09 Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias

Country Status (17)

Country Link
US (2) US6410747B1 (hu)
EP (1) EP0949920B1 (hu)
JP (1) JP4522499B2 (hu)
AT (1) ATE311876T1 (hu)
AU (1) AU749088C (hu)
BR (1) BR9806184A (hu)
CA (1) CA2264750C (hu)
CZ (1) CZ297533B6 (hu)
DE (1) DE69832688T2 (hu)
DK (1) DK0949920T3 (hu)
ES (1) ES2255170T3 (hu)
HU (1) HUP0003852A3 (hu)
IL (2) IL128877A0 (hu)
MX (1) MXPA04001462A (hu)
PL (1) PL191402B1 (hu)
SI (1) SI0949920T1 (hu)
WO (1) WO1999002154A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488280B1 (en) * 2000-09-27 2002-12-03 Milestone Entertainment Games, and methods and apparatus for game play in games of chance
CA2465534C (en) 2000-11-02 2009-10-27 Nigel H. Greig Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
EP1689704A2 (en) * 2003-10-21 2006-08-16 CoLucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
US20070129350A1 (en) * 2004-01-30 2007-06-07 Axonyx, Inc. Methods for treatment of diabetes
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
US20050272804A1 (en) * 2004-06-08 2005-12-08 Axonyx, Inc Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
US20060105940A1 (en) * 2004-11-03 2006-05-18 Axonyx, Inc. Compound useful in the treatment or prevention of cognitive disorders associated with diabetes and associated methods
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
KR100701798B1 (ko) 2005-05-04 2007-03-30 라이브켐 주식회사 해조식물로부터 추출한 콜린에스터라제 활성 억제제를함유하는 알츠하이머성 치매 개선제 및 인지능력 개선제
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
WO2006138385A2 (en) * 2005-06-14 2006-12-28 Cancog Technologies Inc.24 Use of phenserine and analogs to treat behavioral problems and improve trainability
US9757399B2 (en) 2006-10-31 2017-09-12 Jal Therapeutics, Inc. Butyrylcholinesterase inhibitors
WO2008055249A2 (en) * 2006-10-31 2008-05-08 Mgp Biotechnologies, Inc. Butyrylcholinesterase inhibitors and their use in the treatment of neurodegenerative diseases
EP2182938A2 (en) * 2007-07-18 2010-05-12 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
AU2009229372C1 (en) 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
AU2009285584B2 (en) 2008-08-29 2015-04-02 Treventis Corporation Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system
WO2010067594A1 (ja) * 2008-12-11 2010-06-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘキサヒドロピロロインドール誘導体
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
US20120225922A1 (en) * 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
BR112015004902A2 (pt) 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos
KR101667215B1 (ko) 2014-10-21 2016-10-18 한밭대학교 산학협력단 신규한 트립타민 컨쥬게이트 화합물 및 그의 용도
US10149828B2 (en) 2015-01-09 2018-12-11 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans
CN109535157B (zh) * 2018-12-03 2021-10-15 江苏科技大学 一种半蜡梅碱类似物、其合成方法及其用途
KR102233120B1 (ko) 2018-12-18 2021-03-29 한밭대학교 산학협력단 신규한 파에오놀-트립타민 화합물 및 그의 용도
WO2021142221A1 (en) * 2020-01-10 2021-07-15 The Regents Of The University Of California Compositions and methods for the treatment of neurodegenerative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791107A (en) * 1986-07-16 1988-12-13 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use
US4900748A (en) * 1988-03-04 1990-02-13 The United States Of America As Represented By The Department Of Health And Human Services Carbamates related to (-)-physostigmine as cholinergic agents
AU667318B2 (en) * 1991-09-26 1996-03-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases
DK0606366T3 (da) * 1991-09-26 2003-10-06 Us Gov Health & Human Serv Substituerede phenseriner og phenylcarbamater af (-)-eserolin, (-)-N1-noreserolin og (-)-N1-benzylnoreserolin som specifikke inhibitorer af acetylcholinesterase
US5171750A (en) * 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
US5409948A (en) * 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
US7166824B2 (en) * 2002-03-12 2007-01-23 Matsushita Electric Industrial Co., Ltd. High-frequency heating apparatus and control method thereof

Also Published As

Publication number Publication date
JP2001500165A (ja) 2001-01-09
ES2255170T3 (es) 2006-06-16
JP4522499B2 (ja) 2010-08-11
HUP0003852A3 (en) 2003-04-28
MXPA04001462A (es) 2005-04-29
DK0949920T3 (da) 2006-04-18
EP0949920A1 (en) 1999-10-20
AU8293198A (en) 1999-02-08
WO1999002154A1 (en) 1999-01-21
ATE311876T1 (de) 2005-12-15
EP0949920B1 (en) 2005-12-07
DE69832688T2 (de) 2006-09-07
EP0949920A4 (en) 2003-04-23
US6683105B2 (en) 2004-01-27
BR9806184A (pt) 2001-06-19
PL332078A1 (en) 1999-08-30
IL128877A (en) 2007-10-31
SI0949920T1 (sl) 2006-10-31
CA2264750C (en) 2009-06-16
CZ81699A3 (cs) 2000-01-12
CA2264750A1 (en) 1999-01-21
IL128877A0 (en) 2000-01-31
CZ297533B6 (cs) 2007-01-03
AU749088C (en) 2005-11-03
AU749088B2 (en) 2002-06-20
US6410747B1 (en) 2002-06-25
DE69832688D1 (de) 2006-01-12
US20020094999A1 (en) 2002-07-18
PL191402B1 (pl) 2006-05-31

Similar Documents

Publication Publication Date Title
HUP0003852A2 (hu) Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására
GB0223040D0 (en) Therapeutic compounds
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE385794T1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
NO20034056D0 (no) Proliferative sykdommer
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
EE200300559A (et) Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
ATE386520T1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
HUP0302738A2 (hu) SARP-1 alkalmazása scleroderma kezelésére és megelőzésére
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
HUP0300566A2 (hu) Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
ATE286390T1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
FR2718027B1 (fr) Produit destiné au traitement et à la prévention des alopécies.